학술논문
EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective
Document Type
Abstract
Author
Source
In Value in Health July 2022 25(7) Supplement:S361-S361
Subject
Language
ISSN
1098-3015